NCT06736704 2026-03-13
SNV4818 in Participants With Advanced Solid Tumors
Pikavation Therapeutics, Inc.
Phase 1/2 Recruiting
Clinical Trials
68 trialsNCT07459998 2026-03-10
SKB103 for Injection in Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07460375 2026-03-10
A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors
LigaChem Biosciences, Inc.
Phase 1/2 Not yet recruiting
NCT05951608 2026-03-05
A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors
Akeso
Phase 1/2 Active not recruiting
NCT05083481 2026-02-27
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Astellas Pharma Inc
Phase 1/2 Recruiting
NCT07328217 2026-02-11
A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors
Dizal Pharmaceuticals
Phase 1/2 Recruiting
NCT07359066 2026-02-05
An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors
Shanghai SciBrunch Therapeutics Co., Ltd.
Phase 1/2 Recruiting
NCT06697197 2026-02-03
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT07266428 2026-02-03
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
Ottimo Pharma Limited
Phase 1/2 Recruiting
NCT04626635 2026-02-02
COMBINE-EGFR-1
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT07380386 2026-02-02
SKB105 for Injection in Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1/2 Not yet recruiting
NCT05867420 2026-01-27
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
AskGene Pharma, Inc.
Phase 1/2 Recruiting
NCT07093970 2026-01-22
A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors
Lepu Biopharma Co., Ltd.
Phase 1/2 Recruiting
NCT06556108 2026-01-20
ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors
Xinqiao Hospital of Chongqing
Phase 1/2 Completed
NCT07253116 2026-01-14
A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors
Nanjing Jingao biomidical technology Co. Ltd.
Phase 1/2 Recruiting
NCT06741644 2026-01-09
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1/2 Recruiting
NCT07131202 2026-01-08
A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors
Suzhou Forlong Biotechnology Co., Ltd
Phase 1/2 Recruiting
NCT07327294 2026-01-08
A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor
Evopoint Biosciences Inc.
Phase 1/2 Not yet recruiting
NCT05774873 2026-01-06
The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334.
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2 Completed
NCT05277168 2026-01-02
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Recruiting
NCT06459973 2025-12-23
A Clinical Study of YL205 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Recruiting
NCT05134948 2025-12-03
RELATIVITY 059
Bristol-Myers Squibb
Phase 1/2 Completed
NCT06703177 2025-12-03
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
NCT06840821 2025-12-02
Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors
Mainline Biosciences (Shanghai) Co., Ltd
Phase 1/2 Recruiting
NCT07241936 2025-11-28
A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1/2 Recruiting
NCT07019779 2025-11-17
Study of CM518D1 in Patients With Advanced Solid Tumors
Keymed Biosciences Co.Ltd
Phase 1/2 Recruiting
NCT07222969 2025-10-30
A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors
Vibrant Sciences Limited
Phase 1/2 Not yet recruiting
NCT06520488 2025-09-22
A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Recruiting
NCT07170787 2025-09-12
A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1/2 Not yet recruiting
NCT06376136 2025-08-13
A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors
Bio-Thera Solutions
Phase 1/2 Recruiting
NCT06208410 2025-07-25
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
Risen (Suzhou) Pharma Tech Co., Ltd.
Phase 1/2 Recruiting
NCT07060989 2025-07-11
NTS071
Nutshell Therapeutics (Shanghai) Co., LTD.
Phase 1/2 Not yet recruiting
NCT07061639 2025-07-11
A Study of QLS5133 Monotherapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07049458 2025-07-03
Study of CHO-A04 in Advanced Solid Tumors
Cho Pharma Inc.
Phase 1/2 Not yet recruiting
NCT06214143 2025-03-12
A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1/2 Recruiting
NCT05773820 2025-02-10
A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT06787950 2025-01-22
Clinical Study of ASN-3186 in Patients with Advanced Solid Tumors
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Phase 1/2 Not yet recruiting
NCT06782334 2025-01-17
AMT-116 in Patients with Solid Tumors
Multitude Therapeutics Inc.
Phase 1/2 Recruiting
NCT06643754 2025-01-08
A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
NCT06417554 2024-12-31
A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT03379259 2024-10-26
Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
Phase 1/2 Terminated
NCT04068519 2024-10-26
Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody
BeiGene
Phase 1/2 Completed
NCT06605222 2024-10-18
A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT05824455 2024-09-05
A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors
Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd.
Phase 1/2 Terminated
NCT06439589 2024-07-05
Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT04856774 2024-06-27
Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Completed
NCT06474455 2024-06-25
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT05865925 2024-04-25
Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors
Luye Pharma Group Ltd.
Phase 1/2 Enrolling by invitation
NCT06314373 2024-03-18
A Study for HSK39775 in Participants With Solid Tumors
Haisco Pharmaceutical Group Co., Ltd.
Phase 1/2 Recruiting
NCT05430555 2024-02-07
IMAG1NE
T-knife GmbH
Phase 1/2 Terminated